Harmful metals found in vapors from tank-style electronic cigarettes

Medical Xpress | September 27, 2019

A team of scientists at the University of California, Riverside, has found the concentration of metals in electronic cigarette aerosols—or vapor—has increased since tank-style electronic cigarettes were introduced in 2013. Electronic cigarettes, which consist of a battery, atomizing unit, and refill fluid, are now available in new tank-style designs, equipped with more powerful batteries and larger capacity reservoirs for storing more refill fluid. But the high-power batteries and atomizers used in these new styles can alter the metal concentrations that transfer into the aerosol. "These tank-style e-cigarettes operate at higher voltage and power, resulting in higher concentrations of metals, such as lead, nickel, iron, and copper, in their aerosols," said Monique Williams, a postdoctoral researcher in the Department of Molecular, Cell, and Systems Biology, and the first author of the research paper that appears today in Scientific Reports. "Most of the metals in e-cigarette aerosols likely come from the nichrome wire, tin solder joints, brass clamps, insulating sheaths, and wicks—components of the atomizer unit."

Spotlight

Across the population, we’ll do more to tackle health inequalities if we’re able to reduce smoking rates in more disadvantaged groups. We’ll also address the unacceptably high numbers of people dying from smoking related diseases: 78,200 in 2013. This resource sets out the actions that PHE, together with its stakeholders, can take to boost the numbers of people who try to quit and succeed.


Other News
HEALTH TECHNOLOGY

Future Health announced today that it has completely digitalised its annual in-person event at ExCeL London

Future Health | March 02, 2021

Future Health has completely rebranded during lockdown, and the flagship face-to-face event Future Health Innovations at ExCeL is now complemented by a global virtual conference series, under the brand UK Health Week. Free for delegates to attend, it is CPD and CME accredited. Participants will be able to connect, meet buyers and partake in cross border purchasing, education and deal making, enabling an increased ROI and profitable encounters with its AI powered networking software. Further Health Weeks are being rolled out around the world over the course of the coming months, and will be territory specific. Dawn Barclay-Ross, Event Director commented: “I think there will always be a place for face-to-face events; and we are contracted with ExCeL for a live ‘in person’ event four years in advance to 2025. However, as a result of international travel restrictions, health professionals in global markets are looking for on-line engagement”. Future Health offers buyers and sellers the ability to operate on line, and to research and access the products and services that their hospitals and citizens desperately need. Dawn concluded, “In the immediate post COVID era, health buyers want to be able to operate from the comfort of their desk or smart device, and they now can, from literally anywhere in the world”. AboutFuture Health Future Health is an independent exhibition and conference organiser, based in London in the UK. For further information regarding exhibiting, visiting and sponsorship opportunities at Future Health Innovations or UK Health Week Please call +44 (0) 208 012 8511 Email: hello@futurehealthinnovations.com or to sign up to the Future Health platform, register at www.futurehealthinnovations.com

Read More

FUTURE OF HEALTHCARE

SandboxAQ and Mount Sinai Health System Collaborate on Data Protection

Sandbox AQ | March 24, 2022

Sandbox AQ, an enterprise SaaS company leveraging quantum tech and AI, announced a collaboration with Mount Sinai Health System to launch Post-Quantum Cryptography solutions, a broad security technology solution to protect patient data against current and future cybersecurity threats. Sandbox has developed SaaS-based enterprise modules that incorporate the latest encryption protocol standards recently ratified by NIST (National Institute of Standards and Technology). Through Sandbox AQ, Mount Sinai Health System will incorporate PQC protocols into its network to provide increased security for millions of customers and their sensitive data. "Our collaboration with Sandbox AQ propels our security and technology strategies forward, enabling us to deliver advanced, secure cutting-edge products to our patients. Protecting patient data against cyber threats is incredibly important to us." Kristin Myers, Executive Vice President and Chief Information Officer at Mount Sinai Health System and Dean for Information Technology at Icahn School of Medicine at Mount Sinai "Quantum technology will quickly render today's RSA-based encryption obsolete, which is why it's imperative that we protect the world's sensitive data now against the next generation of cyberattacks," said Jack D. Hidary, CEO of Sandbox AQ, which officially launched today. "Mount Sinai is one of the first healthcare systems planning to implement PQC protocols into its health network to protect its customers and transform its business. We look forward to collaborating with them on this project." About SandboxAQ Sandbox AQ is an enterprise SaaS company delivering solutions at the nexus of quantum tech and AI. Based in Palo Alto, the inspiration for Sandbox AQ and some of the team originated at Alphabet Inc. in 2016. Sandbox AQ launched as an independent, venture-backed entity in 2022. About Mount Sinai Health System The Mount Sinai Health System is New York City's largest academic medical system, encompassing eight hospitals, a leading medical school, and a vast network of ambulatory practices throughout the greater New York region. We advance medicine and health through unrivaled education and translational research and discovery to deliver care that is the safest, highest-quality, most accessible and equitable, and the best value of any health system in the nation. The Health System includes approximately 7,300 primary and specialty care physicians; 13 free-standing joint-venture centers; more than 410 ambulatory practices throughout the five boroughs of New York City, Westchester, and Long Island; and more than 30 affiliated community health centers. The Mount Sinai Hospital is ranked in U.S. News & World Report's "Honor Roll" of the top 20 U.S. hospitals and among the top in the nation by specialty: No. 1 in Geriatrics and top 20 in Cardiology/Heart Surgery, Diabetes/Endocrinology, Gastroenterology/GI Surgery, Neurology/Neurosurgery, Orthopedics, Pulmonology/Lung Surgery, Urology, and Rehabilitation. Mount Sinai Kravis Children's Hospital is ranked in U.S. News & World Report's "Best Children's Hospitals" among the country's best in four out of 10 pediatric specialties. New York Eye and Ear Infirmary of Mount Sinai is ranked among the Top 20 nationally for ophthalmology. The Icahn School of Medicine at Mount Sinai is one of three medical schools that have earned distinction by multiple indicators: ranked in the top 20 by U.S. News & World Report's "Best Medical Schools," aligned with a U.S. News & World Report "Honor Roll" Hospital, and No. 14 in the nation for National Institutes of Health funding. Newsweek's "The World's Best Smart Hospitals" ranks The Mount Sinai Hospital as No. 1 in New York and top five globally, and Mount Sinai Morningside as top 20 globally, and "The World's Best Specialized Hospitals" ranks Mount Sinai Heart as No. 1 in New York and No. 4 globally and the Division of Gastroenterology as No. 3 globally, and the Division of Pulmonary Medicine as No. 6 globally.

Read More

MEDICAL DEVICES

Astorg Acquires Majority Interest in Avania

Avania | June 21, 2022

Avania, the preeminent, full-service global MedTech contract research organization announced that Astorg has acquired a majority stake in the company. Astorg, together with Kester Capital current investor who intends to retain a minority stake will actively support management’s plans to advance Avania’s development as a MedTech solution provider. Headquartered in the Netherlands, Avania was formed in March 2020 from the combination of five complementary businesses and started a successful journey to establish a fully integrated platform to serve sponsors worldwide in advancing medical technology products from early development to post-market ensuring customized, scalable solutions that optimize efficiencies and streamline the advancement of medical technology. Astorg brings an impressive global network of relationships in the MedTech space which will strengthen Avania’s pipeline and broaden its customer base while the capital access will help accelerate its growth, both organically and via acquisitions. “The platform we have built has positioned us ahead of our competition in the MedTech CRO space, and this deal will bring additional investment to strengthen our infrastructure, capital for acquisitions, and added support as we continue to grow Avania into the clear market leader. The largest CROs do not have the specialization that we bring, and the regional niche providers do not have the scale and reach of Avania. This unique positioning, along with the continued changes to the MedTech regulatory landscape, will allow us to push ourselves to the next era of growth.” Sapna Hornyak, president and CEO of Avania “We are extremely pleased to partner with Sapna and her team, as well as Kester, on this transaction,” said Managing Partner of Astorg Mid-Cap Edouard Pillot. “Being one of the global leaders in a profitable and fast-growing niche market, Avania squarely fits with Astorg’s investment criteria, and we are delighted to have Avania as our first Mid-Cap Healthcare deal, sitting within Astorg’s broader healthcare portfolio.” About Avania Avania is a leading, global full-service contract research organization focused on the management of clinical studies for medical technology, IVDs, biologics, and device-drug combination products internationally. Avania supports products from the first-in-human phase through the post-market phase with the same customized approach. When you need to advance your medical technology, it takes Avania. Avania’s vision is to be your trusted global partner in the evolution of your medical technology from innovation to commercialization to improving patient health and well-being. About Astorg Astorg is a leading private equity firm with over €17 billion of assets under management. We work with entrepreneurs and management teams to acquire market-leading global companies headquartered in Europe or the US, providing them with the strategic guidance, governance, and capital they need to achieve their growth goals. Astorg enjoys a distinct entrepreneurial culture, a long-term shareholder perspective, and a lean decision-making body. We have valuable industry expertise in healthcare, software, business-to-business professional services and technology-based industrial companies. Astorg has offices in London, Paris, New York, Frankfurt, Milan and Luxembourg. About Kester Capital Kester Capital is a primary buy-out specialist. Kester focuses on the healthcare, data & information and technology sectors, targeting businesses that require capital in order to unlock their potential.

Read More

HEALTH TECHNOLOGY

HCL Technologies and NEORIS Sign Agreement for Integrated IT Services

HCL Technologies | March 23, 2022

HCL Technologies a leading global technology company, has signed a collaboration agreement with NEORIS, a leading global digital accelerator that co-creates disruptive solutions for digitally aspirational companies. The agreement will bring unique capabilities to clients in global markets, including the ability to increase application usage time, business management operations and integrated IT services. As a result of this collaboration, both companies will be able to expand their operations and access new markets, making them better positioned to explore global markets. NEORIS, with more than 20 years of experience and global presence including operations in Latin America, will strengthen HCL’s presence in territories like Mexico and South America which offer great opportunities for commercial development. With operations in 52 countries, HCL Technologies will aid NEORIS in expanding its business internationally, primarily in the United States, Europe and Asia. Together, NEORIS and HCL Technologies can speed up digital transformation, mitigate risks, empower teams based on product development, create a zero-incident culture and save costs. The solutions that NEORIS and HCL will offer together will focus on complementing approaches and solutions, new technologies and talent development among other areas of expertise. "HCL Technologies and NEORIS will work together to find new business opportunities in a united effort, one where NEORIS will provide the best talent with the best skills in the market to reduce costs, time and risk. We have positioned our centers of excellence to scale and meet the expectations of each business and deliver value. Our partnership enables us to provide the best services and solutions to our clients while positioning them for future success." Marcelo Costa, global head of strategic alliances at NEORIS "We are delighted to offer this unique program to our clients in Latin America who are seeking ways to optimize their teams through best-in-class technology solutions," said Ajay Bahl, corporate vice president, HCL Technologies. "Our collaboration will also contribute to our continuous effort to build a great talent pool in Mexico to deliver industry-best service and capabilities to our customers." About NEORIS NEORIS is a leading global digital accelerator that co-creates disruptive solutions for companies that digitally aspire to increase their connections with customers, employees and stakeholders. The company is made of creative teams with technical experience and deep knowledge of their sectors. Headquartered in Miami, Florida, NEORIS has a network of global delivery centers, design studios, and operations in the United States, Europe, Latin America and India. More information is available at www.NEORIS.com, LinkedIn, and Twitter. About HCL Technologies HCL Technologies (HCL) empowers global enterprises with technology for the next decade, today. HCL’s Mode 1-2-3 strategy, based on its deep-domain industry expertise, customer-centricity and entrepreneurial culture of Ideapreneurship™, enables businesses to transform into next-gen enterprises. HCL offers its services and products through three business units: IT and Business Services (ITBS), Engineering and R&D Services (ERS) and Products & Platforms (P&P). ITBS enables global enterprises to transform their businesses through offerings in the areas of applications, infrastructure, digital process operations and next generational digital transformation solutions. ERS offers engineering services and solutions in all aspects of product development and platform engineering HCL Technologies (HCL) empowers global enterprises with technology for the next decade, today. HCL’s Mode 1-2-3 strategy, based on its deep-domain industry expertise, customer-centricity and entrepreneurial culture of Ideapreneurship™, enables businesses to transform into next-gen enterprises. HCL offers its services and products through three business units: IT and Business Services (ITBS), Engineering and R&D Services (ERS) and Products & Platforms (P&P). ITBS enables global enterprises to transform their businesses through offerings in the areas of applications, infrastructure, digital process operations and next generational digital transformation solutions. ERS offers engineering services and solutions in all aspects of product development and platform engineering

Read More

Spotlight

Across the population, we’ll do more to tackle health inequalities if we’re able to reduce smoking rates in more disadvantaged groups. We’ll also address the unacceptably high numbers of people dying from smoking related diseases: 78,200 in 2013. This resource sets out the actions that PHE, together with its stakeholders, can take to boost the numbers of people who try to quit and succeed.

Resources